Alpha Stem Cell Clinics Trials

The Alpha Stem Cell Clinics Network is pursuing its goal to accelerate the development and delivery of stem cell treatments to patients through high quality clinical trials. 

Browse the list of ongoing trials at Alpha Stem Cell Clinic locations in the table below. You can sort trials based on different fields by clicking on the appropriate column header. Trials are automatically listed by status of trial enrollment and Alpha Clinic location.

Alpha Clinic Trials

Alpha Clinicsort descending Alpha Clinic Contact Trial Sponsor Disease Indication Clinical Trial Name Status of Enrollment Learn More
UCI
UCI Stem Cell Clinic
(949) 824-3990
stemcell@uci.edu
BrainStorm Cell Therapeutics Amyotrophic Lateral Sclerosis (ALS) A phase 3, randomized, double-blind, placebo-controlled multicenter study to evaluate efficacy and safety of repeated administrations of NurOwn® (autologous mesenchymal stem cells secreting neurotrophic factors) in participants with ALS Recruiting
UCI
UCI Stem Cell Clinic
(949) 824-3990
stemcell@uci.edu
Stratetech Burn wounds StrataGraft® Skin Tissue in the Promotion of Autologous Skin Regeneration of Complex Skin Defects Due to Thermal Burns That Contain Intact Dermal Elements Active, not recruiting
UCI
& UC Davis
UCI Stem Cell Clinic
(949) 824-3990
stemcell@uci.edu
UC Davis: Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
Humacyte Kidney Failure An Assessment of Humacyte's Human Acellular Vessel in Patients Needing Renal Replacement Therapy: A Comparison With ePTFE Grafts as Conduits for Hemodialysis (HUMANITY) Active, not recruiting
UCI
UCI Stem Cell Clinic
(949) 824-3990
stemcell@uci.edu
ImmunoCellular Therapeutics Cancer - Brain A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma No longer active
UCI
UCI Stem Cell Clinic
(949) 824-3990
stemcell@uci.edu
SanBio Stroke Study of Modified Stem Cells in Patients With Chronic Motor Deficit From Ischemic Stroke No longer active
UCI
& UC Davis
UCI Stem Cell Clinic: Roy Fujitani
949-824-3990
stemcell@uci.edu
Humacyte Kidney failure A Phase 3 Study to Compare the Efficacy and Safety of Humacyte's Human Acellular Vessel With That of an Autologous Arteriovenous Fistula in Subjects With End Stage Renal Disease Recruiting
UCI
UCI Stem Cell Clinic
(949) 824-3990
stemcell@uci.edu
Pluristem Ltd. Critical Limb Ischemia (CLI) A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Phase III Study to Evaluate the Efficacy, Tolerability and Safety of Intramuscular Injections of PLX-PAD for the Treatment of Subjects with Critical Limb Ischemia (CLI) with Minor Recruiting
UCI
UCI Stem Cell Clinic
(949) 824-3990
stemcell@uci.edu
jCyte Eye - Retinitis Pigmentosa (RP) Safety of a Single, Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Retinitis Pigmentosa No longer active
UCI
UCI Stem Cell Clinic
(949) 824-3990
stemcell@uci.edu
ReNeuron Limited Stroke A Randomized, Placebo-Controlled Study of the Efficacy and Safety of Intracerebral Stem Cells (CTX0E03) in Subjects with Disability Following an Ischemic Stroke (PISCES III) Recruiting
UCI
UCI Stem Cell Clinic
(949) 824-3990
stemcell@uci.edu
Longeveron Aging frailty Phase IIb Trial to Evaluate Longeveron Mesenchymal Stem Cells to Treat Aging Frailty Active, not recruiting
UCI
& UCSD & UC Davis
UCI Stem Cell Clinic
949-824-3990
stemcell@uci.edu
Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
Aivita Biomedical Cancer - Brain Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Newly Diagnosed Glioblastoma Recruiting
UCSD Persimmune, Inc. Cancer - Blood Personalized Adoptive Cellular Therapy Targeting MDS Stem Cell Neoantigens (PACTN) Recruiting
UCSD Neuralstem Spinal Cord Injury Safety Study of Human Spinal Cord-derived Neural Stem Cell Transplantation for the Treatment of Chronic SCI Recruiting
UCSD UCSD Cancer - Leukemia Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961 No longer active
UCSD Viacyte Diabetes - Type 1 Three Year Follow-up Safety Study in Subjects Previously Implanted With VC-01 Recruiting
UCSD Asterias Biotherapeutics Spinal Cord Injury Dose Escalation Study of AST-OPC1 in Spinal Cord Injury No longer active
UCSD
UCSD Stem Cell Clinic
(844) 317-7836
alphastemcellclinic@ucsd.edu
Persimmune, Inc. Cancer - Blood Collection of Bone Marrow, Peripheral Blood (PB), Epithelial Tissue, and Saliva Samples From Patients With Myelodysplastic Syndromes (MDS) to Identify MDS-Specific Antigens Recruiting
UCSD Viacyte Diabetes - Type 1 A Safety, Tolerability, and Efficacy Study of VC-01™ Combination Product in Subjects With Type I Diabetes Mellitus Recruiting
UCSD UCSD Cancer - Leukemia UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia No longer active
UCSD
Barbara Parker, MD
858-822-6135
baparker@ucsd.edu
Rebecca Shatsky, MD
858-657-7000
rshatsky@ucsd.edu
UCSD Cancer - Breast Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer Recruiting
UCSD Mesoblast Heart Failure The Purpose of This Study is to Evaluate the Efficacy and Safety of a Allogeneic Mesenchymal Precursor Cells (CEP-41750) for the Treatment of Chronic Heart Failure Recruiting
UCSD Viacyte Diabetes - Type 1 A Safety, Tolerability, and Efficacy Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus and Hypoglycemia Unawareness Recruiting
UCSD
& City of Hope
UCSD Cancer - Leukemia A Study of the Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies Recruiting
UCSD
Teresa Rzesiewicz
844-317-7836
alphstemcellclinic@ucsd.edu
Discgenics Degenerative Disc Disease Study to Evaluate the Safety and Preliminary Efficacy of IDCT, a Treatment for Symptomatic Lumbar Intervertebral Disc Degeneration Recruiting
UCLA
& UCI
UCLA: Courtney Real, BSN
310-267-7433
creal@mednet.ucla.edu
UCI: UCI Stem Cell Clinic
(949) 824-3990
stemcell@uci.edu
SanBio Brain Injury A Double-Blind, Controlled Phase 2 Study of the Safety and Efficacy of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Traumatic Brain Injury (TBI) Active, not recruiting
UCLA
Kit L Shaw, PhD
(310) 267-0584
kshaw@mednet.ucla.edu
Orchard Therapeutics Severe Combined Immunodeficiency (SCID) Efficacy and Safety of a Cryopreserved Formulation of Autologous CD34+ Hematopoietic Stem Cells Transduced Ex Vivo With EFS Lentiviral Vector Encoding for Human ADA Gene in Subjects With ADA Deficiency Severe Combined Immunodeficiency Active, not recruiting
UCLA
Kit L Shaw, PhD
(310) 267-0584
kshaw@mednet.ucla.edu
UCLA Severe Combined Immunodeficiency (SCID) Autologous Transplant of EFS-ADA Modified Bone Marrow Cells for ADA-Deficient Severe Combined Immunodeficiency (SCID) No longer active
UCLA
Fabrizia Urbinati, PhD
(310) 794-1884
furbinati@ucla.edu
UCLA Sickle Cell Disease Stem Cell Gene Therapy for Sickle Cell Disease Recruiting
UCLA
Sarah Larson, MD
310-206-8477
slarson@mednet.ucla.edu
UCLA Cancer TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma (NYSCT MM) No longer active
UCLA
Caroline Kuo, MD
310-794-1940
ckuo@mednet.ucla.edu
UCLA X-linked Chronic Granulomatous Disease Study of Gene Therapy Using a Lentiviral Vector to Treat X-linked Chronic Granulomatous Disease Recruiting
UCLA
Scott Nowicki, MD, PhD
Ignacio Baselga Carretero, PhD
310-206-2090
IBaselga@mednet.ucla.edu
UCLA Cancer - Solid Tumors Adoptive Transfer of NY-ESO-1 TCR Engineered Peripheral Blood Mononuclear Cells (PBMC) and Peripheral Blood Stem Cells (PBSC) After a Myeloablative Conditioning Regimen, With Administration of Interleukin-2, in Patients With Advanced Malignancies Recruiting
UCLA
Lia Etheridge
(310-825-7174)
letheridge@mednet.ucla.edu
UCLA Cancer - Lung A Phase I trial of intratumoral administration of CCL21-gene modified dendritic cell (DC) combined with intravenous pembrolizumab for advanced NSCLC Recruiting
UCLA
Maricela Gonzalez
(310) 557-3729
mmgonzalez@mednet.ucla.edu
Calimmune HIV/AIDS Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection No longer active
City of Hope
& UCLA
City of Hope: Amrita Krishnan, MD
(626) 256-4673 ext 62405
AKrishnan@coh.org
UCLA: Maricella Gonzalez
310-557-3729
mmgonzalez@mednet.ucla.edu
City of Hope HIV/AIDS Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected Patients Recruiting
City of Hope
Cara Nolan
626-256-4673 ext 32341
cnolan@coh.org
Juno Therapeutics Cancer - Leukemia Long-Term Follow-up Study for Patients Previously Treated With JCAR015 No longer active
City of Hope
Erminia Massarelli
626-218-9200
emassarelli@coh.org
Tessa Therapeutics Cancer - Nasopharyngeal Carcinoma A Multicentre, Randomized, Open-Label, Phase III Clinical Trial Of Gemcitabine And Carboplatin Followed By Epstein-Barr Virus-Specific Autologous Cytotoxic T Lymphocytes Versus Gemcitabine And Carboplatin As First Line Treatment For Advanced Nasopharyngea Recruiting
City of Hope
Jana Portnow, MD
(626) 256-4673 ext 62909
jportnow@coh.org
City of Hope Cancer - Brain Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas Active, not recruiting
City of Hope
Behnam Badie, MD;
626-256-4673
bbadie@coh.org
City of Hope Cancer - Brain Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma Recruiting
City of Hope
Jana Portnow, MD
(626) 256-4673 ext 62909
jportnow@coh.org
City of Hope Cancer - Brain Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas Recruiting
City of Hope
Myo Htut, MD
626-218-2405 ext 82405
mhtut@coh.org
Juno Therapeutics Cancer - Myeloma Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma (EVOLVE) Recruiting
City of Hope
Amrita Krishnan, MD
(626) 256-4673 ext 62405
AKrishnan@coh.org
City of Hope Cancer - Lymphoma (AIDS-Related) Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma Active, not recruiting
City of Hope
Joseph Rosenthal, MD
626-256-4673 ext 88442
jrosenthal@coh.org
City of Hope Sickle Cell Disease Safety of Blood Stem Cell Mobilization With Plerixafor in Patients With Sickle Cell Disease (PISMO) Recruiting
City of Hope
Behnam Badie, MD
(626) 256-4673 ext 60098
bbadie@coh.org
City of Hope Cancer - Brain Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma Recruiting
City of Hope
Fatemeh Bidmeshki
626-218-9393
fbidmeshki@coh.org
City of Hope Cancer - Brain HER2-CAR T Cells in Treating Participants With Brain or Leptomeningeal Metastases Recruiting
City of Hope
Alex Herrera, MD
626-218-2405
aherrera@coh.org
Kite Pharma Cancer - Lymphoma Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma (ZUMA-12) Recruiting
City of Hope
L. Elizabeth Budde, MD, PhD
(626) 256-4673
ebudde@coh.org
City of Hope Cancer - Leukemia Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Recruiting
City of Hope
Nadia Ewing, MD
(626) 256-4673 x89200
newing@coh.org
Sangamo Therapeutics Hemophilia A Dose-Ranging Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 in Subjects With Severe Hemophilia A Recruiting
City of Hope
Cheryl De Guzman
626-218-5613
CDeGuzman@coh.org
Children's Hospital Los Angeles Infection After Stem Cell Transplant Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Recruiting
City of Hope
Anthony Stein, MD
626-218-2405
stein@coh.org
Precision BioSciences, Inc. Cancer - Lymphoma Dose-escalation Study of Safety of PBCAR0191 in Patients With r/r NHL and r/r B-cell ALL Recruiting
City of Hope
Karen Reckamp, MD
(626) 256-4673 x89200
kreckamp@coh.org
Adaptimmune Cancer - Lung A Phase I/ II Dose Escalation Open Label Clinical Trial Evaluating the Safety and Efficacy of MAGE A10ᶜ⁷⁹⁶T in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC) Active, not recruiting

Pages

Clinical trials conducted at CIRM Alpha Stem Cell Clinics must comply with applicable federal and state laws and medical and ethical standards governing the conduct of human clinical trials.

Find Out More:
About Alpha Stem Cell Clinics
Alpha Clinics News